Antiresorptive Drug-Related Osteonecrosis of the Jaw

Dental Clinics of North America

Volumn 58, Issue 2, 2014, Pages 369-384

  Uyanne, Jettie ^a,b   Calhoun, Colonya C ^b,c   Le, Anh D ^a,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bisphosphonate; Denosumab; Osteonecrosis of the jaw; Zoledronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; DENOSUMAB; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR;

ANTAGONISTS AND INHIBITORS; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; CHEMICALLY INDUCED; HUMAN; JAW DISEASES; OSTEONECROSIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; JAW DISEASES; OSTEONECROSIS; RANK LIGAND;

EID: 84896346446     PISSN: 00118532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cden.2013.12.006     Document Type: Review

References (87)

1. Ruggiero S.L., Fantasia J., Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006, 102(4):433-441.
2. AAOMS: Advisory Task Force on Bisohosphonate-related Osteonecrosis of theJaws, American Association of Oral and Maxillofacial Surgeons American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. JOral Maxillofac Surg 2007, 65:369-376.
3. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaws: report of a task force of the American Society for Bone and Mineral Research. JBone Miner Res 2007, 22:1479-1491.
4. Ruggiero S.L. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): initial discovery and subsequent development. JOral Maxillofac Surg 2009, 67(Suppl 5):13-18.
5. Allen M. The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing. Odontology 2011, 99:8-17.
6. Hellstein J.W., Adler R.A., Edwards B., et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis. JAm Dent Assoc 2011, 142(11):1243-1251.
7. Allen M.R., Burr D.B. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. JOral Maxillofac Surg 2009, 67(Suppl 5):61-70.
8. Lipton A., Steger G.G., Figueroa J., et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. JClin Oncol 2007, 25:4431-4437.
9. Ruggiero S.L., Drew S.J. Osteonecrosis of the jaws and bisphosphonate therapy. JDent Res 2007, 86:1013-1021.
10. Freiberger J.J. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. JOral Maxillofac Surg 2009, 67(Suppl 5):96-106.
11. Reszka A.A., Rodan G.A. Bisphosphonate mechanism of action. Curr Rheumatol Rep 2003, 5:65-74.
12. Rogers M.J., Gordon S., Benford H.L., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000, 88:2961-2978.
13. Van den Wyngaert T., Huizing M.T., Vermorken J.B. Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?. Ann Oncol 2006, 17:1197-1204.
14. Brown-Glaberman U., Stopeck A.T. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors. Biologics 2012, 6:89-99.
15. Fleisher K.E., Jolly A., Venkata U.D.C., et al. Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy. JOral Maxillofac Surg 2013, 71(3):513-519.
16. Silva-Fernandez L., Rosario M.P., Martinez-Lopez J.A., et al. Denosumab for the treatment of osteoporosis: a systematic literature review. Rheumatalo Clin 2013, 9(1):42-52.
17. Bridgeman M.B., Pathak R. Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review. Clin Ther 2011, 22(11):1547-1559.
18. Steger G., Bartsch R. Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion. Ther Adv Med Oncol 2011, 2(5):233-243.
19. Lacey D.L., Boyle W.J., Simonet W.S., et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 2012, 11(5):401-419.
20. Prolia (Denosumab) [prescribing information] 2010, Amgen, Thousand Oaks (CA).
21. Cavilli L., Brandi M.L. Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility. Ther Clin Risk Manag 2012, 8:253-266.
22. Marx R.E. Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. JOral Maxillofac Surg 2003, 61:1115-1117.
23. Ruggiero S.L., Mehrotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. JOral Maxillofac Surg 2004, 62(5):527-534.
24. Wang J., Goodger N.M., Progel M.A. Osteonecrosis of the jaws associated with cancer chemotherapy. JOral Maxillofac Surg 2003, 61:1104-1107.
25. Dimopoulos M., Kastritis E., Moulopoulos L.A., et al. The incidence of osteonecrosis of the jaw in patients with multiple myeloma who receive bisphosphonates depends on the type of bisphosphonate. Blood 2005, 106:637. [American Society of Hematology Annual Meeting Abstracts].
26. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. JClin Oncol 2005, 23:8580-8587.
27. Drake M.T., Clark B.L., Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008, 83:1032-1045.
28. Wimalawansa S.J. Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. Expert Opin Drug Saf 2008, 7:491-512.
29. Wessel J.H., Dodson T.B., Zavras A.I., et al. Zoledronate, smoking and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. JOral Maxillofac Surg 2008, 66(4):625-631.
30. Tennis P., Rothman K.J., Bohn R.L., et al. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf 2012, 21:810-817.
31. Wang E.P., Kaban L.B., Strewler G.J., et al. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. JOral Maxillofac Surg 2007, 65(7):1328-1331.
32. Gliklich R., Wilson J. Epidemiology of bisphosphonate-related osteonecrosis of the jaw: the utility of a national registry. JOral Maxillofac Surg 2009, 67(4):850-855.
33. Woo S.B., Helllstein J.W., Kalmar J.R. Systemic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006, 144:753-756.
34. Knight R.J.W., Reddy C., Rtshiladze M.A., et al. Bisphosphonate-related osteonecrosis of the jaw: tip of the iceberg. JCraniofac Surg 2010, 21:25-32.
35. Hellstein J.W., Marek C.L. Bis-phossy jaw, phossy jaw, and the 21st century: bisphosphonate-associated complications of the jaws. JOral Maxillofac Surg 2004, 62:1563-1566.
36. Mavrokokki T., Cheng A., et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. JOral Maxillofac Surg 2007, 65:415-423.
37. Ruggiero S.L. Bisphosphonate-related osteonecrosis of the jaw: an overview. Ann N Y Acad Sci 2011, 1218:38-46.
38. Khan A.A., Sándor G.K., Dore E., et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. JRheumatol 2008, 35:1391-1397.
39. Patel S., Choyee S., Uyanne J., et al. Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guideline. Oral Dis 2012, 18(7):625-632.
40. Junquera L., Gallego L. Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant?. JOral Maxillofac Surg 2008, 66(7):1516-1517.
41. Fedele S., Porter S.R., D'Aiuto F., et al. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 2010, 123(11):1060-1064.
42. Vescovi P., Nammour S. Bisphosphonate-related osteonecrosis of the Jaw (BRONJ) therapy. A critical review. Minerva Stomatol 2010, 59(4):181-203. 204-13.
43. Hutchinson M., O'Ryan F., Chavez V., et al. Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure. JOral Maxillofac Surg 2010, 68(9):2232-2240.
44. Bedogni A., Blandamura S., Lokmic Z., et al. Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008, 105(3):358-364.
45. Store G., Larheim T.A. Mandibular osteoradionecrosis: a comparison of computed tomography with panoramic radiography. Dentomaxillofac Radiol 1999, 28(5):295-300.
46. Ficarra G., Beninati F. Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects. Head Neck Pathol 2007, 1(2):132-140.
47. Marx R.E. Reconstruction of defects caused by bisphosphonate-induced osteonecrosis of the jaws. JOral Maxillofac Surg 2009, 67(Suppl 5):107-119.
48. Ganapathy N., Gokulnathan S., Bajan N., et al. Bisphosphonates: an update. JPharm Bioallied Sci 2012, 4(Suppl 2):S410-S413.
49. Arce K., Assael L.A., Weissman J.L. Imaging findings in bisphosphonate-related osteonecrosis of jaws. JOral Maxillofac Surg 2009, 67(Suppl 1):75-84.
50. O'Ryan F.S., Khoury S., Liao W., et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. JOral Maxillofac Surg 2009, 67(7):1363-1372.
51. Unger E., Moldofsky P., Gatenby R., et al. Diagnosis of osteomyelitis by MR imaging. AJR Am J Roentgenol 1988, 150(3):605-610.
52. Scheller E.L., Baldwin C.M., Kuo S., et al. Bisphosphonates inhibit expression of p63 by oral keratinocytes. JDent Res 2011, 90(7):894-899.
53. Coxon F.P., Thompson K., Roelofs A.J., et al. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 2008, 42:848-860.
54. Hansen T., Kunkel M., Springer E., et al. Actinomycosis of the jaws-histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteonecrosis. Virchows Arch 2007, 451:1009-1017.
55. Wolf A.M., et al. The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica 2006, 91:1165-1171.
56. Sedghizadeh P.P., Kumar S.K.S., Gorur A., et al. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. JOral Maxillofac Surg 2008, 66:767-775.
57. Sedghizadeh P.P., Kumar S.K., Gorur A., et al. Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. JAm Dent Assoc 2009, 140:1259-1266.
58. Marx R.E., Sawatari Y., Fortin M., et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. JOral Maxillofac Surg 2005, 63(11):1567-1575.
59. Epstein J., Van Der Meij E., McKenzie M., et al. Postradiation osteonecrosis of the mandible: a long-term follow up study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997, 83:657-662.
60. He H., Lui R., Desta T., et al. Diabetes causes osteoclastogenesis, reduced bone formation and enhanced apoptosis of osteoblastic cell in bacteria stimulated bone loss. Endocrinology 2004, 145:447-452.
61. Henderson B., Nair S.P. Hard labour: bacterial infection of the skeleton. Trends Microbiol 2003, 11:570-577.
62. Sedghizadeh P.P., Yooseph S., Fadrosh D.W., et al. Metagenomic investigation of microbes and viruses in patient with jaw osteonecrosis associated with bisphosphonate therapy. Oral Surg Oral Med Oral Pathol Oral Radiol 2012, 114(6):764-770.
63. Melani C., Sangaletti S., Barazzetta F.M., et al. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007, 67:11438-11446.
64. Kikuiri T., Kim I., Yamaza T., et al. Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. JBone Miner Res 2010, 25(7):1668-1679.
65. Marx R.E. Bisphosphonate-induce osteonecrosis of the jaws: a challenge, a responsibility and an opportunity. Int J Periodontics Restorative Dent 2008, 28:5-6.
66. Lee C.Y., Suzuki J.B. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study. Implant Dent 2010, 19(1):29-38.
67. Baim S., Miller P. Perspective assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. JBone Miner Res 2009, 24:561-574.
68. Bagan J.V., Jimenez Y., Gómez D., et al. Collagen telopeptide (serum CTX) and its relationship with size and number of lesion in osteonecrosis of the jaw in cancer patient on IV bisphosphonate. Oral Oncol 2006, 44:1088-1089.
69. Salem A.M., Zohny S.F., Abd El-Wahab M.M., et al. Predictive value of osteocalcin and β-CrossLaps in metastatic breast cancer. Clin Biochem 2007, 40:1201-1208.
70. Marx R.E., Cillo J.E., Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007, 65(12):2397-2410.
71. Kunchur R., Need A., Hughes T., et al. Clinical Investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. JOral Maxillofac Surg 2009, 67(6):1167-1173.
72. Carlson E.R., Basile J.D. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. JOral Maxillofac Surg 2009, 67(Suppl 5):85-95.
73. Yarom N., Fedele S., Lazarovici T.S., et al. Is exposure of the jawbone mandatory for establishing the diagnosis of bisphosphonate-related osteonecrosis of the jaw?. JOral Maxillofac Surg 2010, 68(3):705.
74. Ruggiero S.L., Dodson T.B., Assael L.A., et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. JOral Maxillofac Surg 2009, 67(Suppl 5):2-12.
75. Mawardi H., Treister N., Richardson P., et al. Sinus tracts-an early sign of bisphosphonate-associated osteonecrosis of the jaws?. JOral Maxillofac Surg 2009, 67(3):593-601.
76. Stanton D.C., Balasanian E. Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases. JOral Maxillofac Surg 2009, 67(5):943-950.
77. Graziani F., Vescovi P., Campisi G., et al. Resective surgical approach shows a high performance in the management of advanced cases of bisphosphonate-related osteonecrosis of the jaws: a retrospective survey of 347 cases. JOral Maxillofac Surg 2012, 70(11):2501-2507.
78. Ruggiero S.L. Emerging concepts in the management and treatment of osteonecrosis of the jaw. Oral Maxillofac Surg Clin North Am 2013, 25(1):11-20.
79. Agrillo F., Filiaci F., Ramieri V., et al. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): 5 year experience in the treatment of 131 cases with ozone therapy. Eur Rev Med Pharmacol Sci 2012, 16(12):1741-1747.
80. Freiberger J.J., Padilla-Burgos R., McGraw T., et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. J Oral Maxillofac Surg 2012, 70(7):1573-1583.
81. Curi M.M., Cossolin G.S.I., Koga D.H., et al. Bisphosphonate-related osteonecrosis of the jaws-an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma. J Oral Maxillofac Surg 2011, 69(9):2465-2472.
82. Epstein M.S., Wicknick F.W., Epstein J.B. Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010, 110:593-596.
83. Harper R., Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 2007, 65(3):573-580.
84. Cheung A., Seeman E. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med 2010, 363(25):2473-2474.
85. Pautke C., Bauer F., Otto S., et al. Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study. J Oral Maxillofac Surg 2011, 69(1):84-91.
86. Martins M.A., Martins M.D., Lascala C.A. Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study. Oral Oncology 2012, 48:79-84.
87. Vescovi P., Merigo E., Manfredi M. Nd:YAG Laser Biostimulation in the Treatment of Bisphosphonate-Associated Osteonecrosis of the Jaw: Clinical Experience in 28 Cases. Photomedicine and Laser Surgery 2008, 26(1):37-46.